Cost-effectiveness of Rule-based Immunoprophylaxis Against Respiratory Syncytial Virus Infections in Preterm Infants

Overview

Journal Eur J Pediatr

Specialty Pediatrics

Date 2017 Nov 24

PMID 29168012

Citations 9

Authors

Maarten O Blanken

Geert W Frederix

Elisabeth E Nibbelke

Hendrik Koffijberg

Elisabeth A M Sanders

Maroeska M Rovers

Louis Bont

Affiliations

Soon will be listed here.

Abstract

Conclusions: Targeted RSV prophylaxis is not cost-effective in reducing RSV burden of disease in moderately preterm infants, but it can become cost-effective if lower priced biosimilar palivizumab or a vaccine would be available.

Citing Articles

Bas T, Duarte V Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065775 PMC: 11279612. DOI: 10.3390/ph17070925.

Healthcare costs related to respiratory syncytial virus in paediatric intensive care units in the Netherlands: a nationwide prospective observational study (the BRICK study).

Phijffer E, Wildenbeest J, Brouwer C, de Hoog M, Kneyber M, Maebe S Lancet Reg Health Eur. 2024; 43:100965.

PMID: 39040526 PMC: 11260872. DOI: 10.1016/j.lanepe.2024.100965.

Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.

Ordonez J, Huertas V BMC Infect Dis. 2024; 24(1):418.

PMID: 38641577 PMC: 11031882. DOI: 10.1186/s12879-024-09300-5.

Human Respiratory Syncytial Virus Infections among Hospitalized Children in Poland during 2010-2020: Study Based on the National Hospital Registry.

Rzad M, Kanecki K, Lewtak K, Tyszko P, Szwejkowska M, Gorynski P J Clin Med. 2022; 11(21).

PMID: 36362679 PMC: 9656302. DOI: 10.3390/jcm11216451.

Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.

Garegnani L, Styrmisdottir L, Roson Rodriguez P, Escobar Liquitay C, Esteban I, Franco J Cochrane Database Syst Rev. 2021; 11:CD013757.

PMID: 34783356 PMC: 8594174. DOI: 10.1002/14651858.CD013757.pub2.

References

Jansen A, Sanders E, Hoes A, van Loon A, Hak E . Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. Eur Respir J. 2007; 30(6):1158-66. DOI: 10.1183/09031936.00034407. View

Anderson E, Carbonell-Estrany X, Blanken M, Lanari M, Sheridan-Pereira M, Rodgers-Gray B . Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons. Pediatr Infect Dis J. 2016; 36(2):160-167. PMC: 5242218. DOI: 10.1097/INF.0000000000001377. View

Bindels P, van de Griendt E, Tuut M, Steenkamer T, Uijen J, Geijer R . [Dutch College of General Practitioners' practice guideline 'Asthma in children']. Ned Tijdschr Geneeskd. 2014; 158:A7935. View

Smyth R, Openshaw P . Bronchiolitis. Lancet. 2006; 368(9532):312-22. DOI: 10.1016/S0140-6736(06)69077-6. View

Gregory S, Kuntz K, Sainfort F, Kharbanda A . Cost-Effectiveness of Integrating a Clinical Decision Rule and Staged Imaging Protocol for Diagnosis of Appendicitis. Value Health. 2016; 19(1):28-35. DOI: 10.1016/j.jval.2015.10.007. View

Houben M, Bont L, Wilbrink B, Belderbos M, Kimpen J, H A Visser G . Clinical prediction rule for RSV bronchiolitis in healthy newborns: prognostic birth cohort study. Pediatrics. 2010; 127(1):35-41. DOI: 10.1542/peds.2010-0581. View

van Eijsden P . Fate of new cancer drug is uncertain in Netherlands, as institute deems it too costly. BMJ. 2015; 351:h6778. DOI: 10.1136/bmj.h6778. View

Simon A, Ammann R, Wilkesmann A, Eis-Hubinger A, Schildgen O, Weimann E . Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database. Eur J Pediatr. 2007; 166(12):1273-83. DOI: 10.1007/s00431-007-0426-y. View

Blanken M, Rovers M, Bont L . Respiratory syncytial virus and recurrent wheeze. N Engl J Med. 2013; 369(8):782-3. DOI: 10.1056/NEJMc1307429. View

10.

Prais D, Schonfeld T, Amir J . Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use. Pediatrics. 2003; 112(3 Pt 1):548-52. DOI: 10.1542/peds.112.3.548. View

11.

Wang D, Bayliss S, Meads C . Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess. 2011; 15(5):iii-iv, 1-124. PMC: 4781126. DOI: 10.3310/hta15050. View

12.

Fekkes M, Theunissen N, Brugman E, Veen S, Verrips E, Koopman H . Development and psychometric evaluation of the TAPQOL: a health-related quality of life instrument for 1-5-year-old children. Qual Life Res. 2001; 9(8):961-72. DOI: 10.1023/a:1008981603178. View

13.

. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014; 134(2):e620-38. DOI: 10.1542/peds.2014-1666. View

14.

Blanken M, Koffijberg H, Nibbelke E, Rovers M, Bont L . Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study. PLoS One. 2013; 8(3):e59161. PMC: 3595233. DOI: 10.1371/journal.pone.0059161. View

15.

Rietveld E, de Jonge H, Polder J, Vergouwe Y, Veeze H, Moll H . Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. Pediatr Infect Dis J. 2004; 23(6):523-9. DOI: 10.1097/01.inf.0000129690.35341.8d. View

16.

Miedema C, Kors A, Ten W, Kimpen J . Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in The Netherlands. Pediatr Infect Dis J. 2001; 20(2):160-3. DOI: 10.1097/00006454-200102000-00008. View

17.

Mazur N, Martinon-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T . Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015; 3(11):888-900. DOI: 10.1016/S2213-2600(15)00255-6. View

18.

Debes A, Gilman R, Onyango-Makumbi C, Ruff A, Oberhelman R, Dowdy D . Cost-effectiveness of Diagnostic Algorithms for Tuberculosis in Children Less Than 5 Years of Age. Pediatr Infect Dis J. 2016; 36(1):36-43. PMC: 5214221. DOI: 10.1097/INF.0000000000001342. View

19.

Isaacs D . Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus? The case against. Paediatr Respir Rev. 2013; 14(2):128-9. DOI: 10.1016/j.prrv.2012.12.006. View

20.

van Giessen A, Peters J, Wilcher B, Hyde C, Moons C, Wit A . Systematic Review of Health Economic Impact Evaluations of Risk Prediction Models: Stop Developing, Start Evaluating. Value Health. 2017; 20(4):718-726. DOI: 10.1016/j.jval.2017.01.001. View